Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

FACULTY

Jerry D. Meece, RPh, CDE, CDM, FACA, FAADE
Director of Clinical Services
Plaza Pharmacy and Wellness Center
Gainesville, TX

Scott R. Drab, PharmD, CDE, BC-ADM
Associate Professor
Pharmacy and Therapeutics
Director, University Diabetes Care Associates
University of Pittsburgh
Pittsburgh, PA

Philip Raskin, MD, FACP, FACE, CDE
Professor of Medicine
Clifton and Betsy Robinson Chair in Biomedical Research
University of Texas Southwestern Medical Center
Dallas, TX

FINANCIAL DISCLOSURE

Jerry D. Meece, RPh, FACA, FAADE, CDM, CDE – Consultant: Animas, AstraZeneca, Johnson and Johnson, Lifescan, Sanofi; Speaker's Bureau: AstraZeneca, Animas, Johnson and Johnson, Lifescan, Lilly, Novo Nordisk and Sanofi.

Scott R. Drab, PharmD, CDE, BC-ADM – Consultant: Becton Dickinson; Speaker's Bureau: GlaxoSmithKline and Novo Nordisk.

Philip Raskin, MD, FACP, FACE, CDE – Grant (PI): Amylin Pharmaceuticals, Andromeda Biotech, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Intarcia, Eli Lilly & Company, Merck, Novo Nordisk, Pfizer, Inc.; Consultant: Boston Therapeutics, GlaxoSmithKline, Janssen Pharmaceutics.

The following reviewer, Gina Ryan has no actual or potential conflict of interest in relation to this program.

Michael Speidel, Medical Logix, LLC and Jennifer Greg hereby state they do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Susanne Batesko, RN, BSN, Michele Salernitano, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

ACCREDITATION STATEMENTS

Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Healthcare Education, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: 0430-0000-16-004-H01-P

Credits: 1.5 hours (0.15 ceu)
Published: January 29, 2016
Expires:  January 31, 2017
Type of Activity: Knowledge

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes

TARGET AUDIENCE

This accredited activity has been designed for pharmacists.

HOW TO EARN CREDIT

During the period January 29, 2016 through January 31, 2017, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on 'Submit Posttest' at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your Statement of Credit will be made available immediately. Click on View Certificate and print the Statement of Credit for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.

GOAL

This activity is designed to inform and educate pharmacy professionals about their role in counseling and preventing hypoglycemia when initiating or intensifying treatment regimens for patients with T2DM.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

1. Identify risk factors for and symptoms of hypoglycemia and make recommendations that promote hypoglycemia awareness in vulnerable patients.
2. Routinely evaluate patients for hypoglycemia.
3. Educate patients as to the signs, symptoms and preventive measures to reduce the risks
   of hypoglycemia.
4. Propose treatment intensification options to optimize glycemic control with a low risk
   of hypoglycemia.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  
• Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  
• Monitor Screen Resolution: 320 x 480 or higher
  
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

DISCLOSURE OF UNLABELED USE AND DISCLAIMER

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Novo Nordisk and Sanofi. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsors promote the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.

Clinical Dialogue Program Description 
Clinical Dialogues are moderated discussions featuring leading experts to deliver the most up-to-date educationally relevant program possible. The interactive 'give-and-take' format of these programs provides for lively discussions between the faculty that distill topics into clinically-pertinent 'need to know' information which users may immediately apply to clinical practice.

eCase Challenge Program Description 
eCase Challenges are text-based case programs where pharmacists are presented with challenging case scenarios and are asked to make patient management recommendations.